EN DE
Watch Grey Cloak Tech Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Grey Cloak Tech Inc (HYEX) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Grey Cloak Tech Inc stock $0.31, price $1.35, that is 76.7% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US42227D1000

GC Grey Cloak Tech Inc logo Thin data Nov 12, 2026

Grey Cloak Tech Inc

HYEX · US

Far too expensive (fair value 77% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Generates free cash flow 
Revenue last quarter +113% vs. a year ago. 
Mixed Growth (revenue 5y +28.7 %/yr in USD) 
Fair value $0.3145 · Strongly overvalued 
Quality 35/100 
Falling price (downtrend) 
Loss-making · -14.0% net margin (TTM) 
Trails peers (2/10) 
Narrow moat 11/100 · thin data
Thin data 
⚠ Dilution⚠ Thinly traded⚠ Small free float
Watch Grey Cloak Tech Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$16.56 $0.8209 Fair Value $0.3145 Dec 2020 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range $0.8209 – $16.56 · fair‑value band $0.1785 – $0.5695 · the $1.35 price screens above the $0.3145 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow Grey Cloak Tech in your weekly email

Every Wednesday you see whether Grey Cloak Tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Healthy Extracts Inc., through its subsidiaries, engages in acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals in the United States. It operates through Corporate and Health Supplements segments.

Show moreShow less

The company's proprietary and patented products target categories within the nutraceuticals market, such as heart, brain, and immune health.

It also provides heart and immune health products, including bergamot-based products in tablet and capsule form; and plant-based health technology neuro-products that enhance brain health comprising memory, cognition, focus, and neuro-energy.

The company was formerly known as Grey Cloak Tech Inc. and changed its name to Healthy Extracts Inc. in October 2020. Healthy Extracts Inc. was incorporated in 2014 and is headquartered in Henderson, Nevada.

Stock analysis

Grey Cloak Tech Inc (HYEX) currently trades at $1.35, while our model-based Fair Value estimate is $0.3145, 77% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $0.3200 per share, and 0 of the 6 models we run sit above the $1.35 price.

Bear case: the Asset-Based group reads lowest at $0.1100, and 6 of the 6 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.1785 (bear) to $0.5695 (bull), the price of $1.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Grey Cloak Tech Inc reported revenue of $4.5M in FY2025 versus $1.5M in FY2021, a compound +32.5%/yr. Reported net income was −$881K in FY2025.

Key figures

Market cap $22.8M Micro · P/S ratio 3.02 · EPS (TTM) $−0.0600 · Net margin −14.0% · Return on equity −7.7% · Return on assets (EBIT) −38.3% (5-year average) · Operating margin −2.4% · Revenue (TTM) $6.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 65% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at −77%, HYEX screens richer than that median.

Fair Value models

Bear $0.1785 Fair Value $0.3145 Bull $0.5695
Price $1.35 · Downside -76.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $0.2200 $0.3400 $0.6800 74
Growth DCF $0.2100 $0.3700 $0.6700 72
5Y Revenue Exit $0.1400 $0.2300 $0.4000 68
All 7 models by family
DCF Models
FCF DCF $0.2200 $0.3400 $0.6800 74
5Y Revenue Exit $0.1400 $0.2300 $0.4000 68
10Y Revenue Exit $0.1700 $0.3200 $0.4100 64
Multiples
EV/Revenue n/a n/a $0.0300 47
Asset-Based
NCAV (Graham) $0.0800 $0.1100 $0.1600 51
Growth DCF
Growth DCF $0.2100 $0.3700 $0.6700 72
Rev-Margin DCF $0.1500 $0.2600 $0.4700 67

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 47
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+44.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−160.8% (2020) → −20.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+51.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +47.6% a year for the price.

HYEX screens overvalued: fair value 77% below the price. Compare with Merck KGaA →

Compare Grey Cloak Tech Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −76.7% · Bottom 25%
Profitability
Return on assets −3.2% · Below median
Net margin (12 months) −14.0% · Bottom 25%
Operating margin (12 months) −2.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 113.4% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.95× · Cheapest 25%
P/S (12 months) 3.62× · Pricier than median
Price / free cash flow (fiscal year) 155.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.57 $113.53 +38% vs HYEX
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.93 ¥53.04 +11% vs HYEX
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,885 ₹1,983 +5% vs HYEX
Haleon plc HLN $9.10 $8.62 −5% vs HYEX
Merck KGaA MRK €148.15 €109.18 −26% vs HYEX
Galderma Group GALD CHF 194.40 CHF 109.80 −44% vs HYEX
Takeda Pharmaceutical Company TAK $20.84 $11.34 −46% vs HYEX
Teva Pharmaceutical Industries Limited TEVA $43.24 $20.74 −52% vs HYEX
Sandoz Group SDZ CHF 86.90 CHF 40.54 −53% vs HYEX
Divi's Laboratories Limited DIVISLAB ₹11,485 ₹1,567 −86% vs HYEX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Grey Cloak Tech Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Grey Cloak Tech Inc Fair Value". https://www.fairvalue-calculator.com/stock/HYEX

Frequently asked questions

Is Grey Cloak Tech Inc (HYEX) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of $0.3145 versus a price of $1.35, about 77% lower (overvalued).
What is the fair value of HYEX?
Our model-based fair value for Grey Cloak Tech Inc is $0.3145 (as of Nov 12, 2026), built from audited fundamentals. The current price: $1.35.
What is the quality score of HYEX?
Grey Cloak Tech Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Grey Cloak Tech Inc (HYEX)?
Our model-based price target is the fair value of $0.3145 (as of Nov 12, 2026) from 7 valuation models. Cautious scenario $0.1785, optimistic scenario $0.5695. It is a calculation from audited fundamentals, not an analyst target.
What is the Grey Cloak Tech Inc stock forecast for 2026?
Our models put fair value at $0.3145, about 77% lower versus a price of $1.35 (overvalued). Cautious scenario $0.1785, optimistic scenario $0.5695. The calculation is refreshed regularly with new filings.
What is the revenue of Grey Cloak Tech Inc (HYEX)?
Grey Cloak Tech Inc reported trailing-twelve-month revenue of about $6.3M (latest available figure, as of Nov 12, 2026).
What growth is priced into Grey Cloak Tech Inc (HYEX)?
For today's price to be fair in a discounted-cash-flow model, Grey Cloak Tech Inc would have to grow free cash flow by +51.2 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +28.7 % per year. As of Nov 12, 2026.
What discount rate (WACC) does the fair value of HYEX use?
Our models discount Grey Cloak Tech Inc at 9.7 %: a base by market capitalisation (nano), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Grey Cloak Tech Inc that is +51.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Grey Cloak Tech Inc (HYEX) delivered so far?
Over the past 5 years revenue at Grey Cloak Tech Inc grew +28.7 % a year. The price currently implies free-cash-flow growth of +51.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Grey Cloak Tech Inc (HYEX) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Grey Cloak Tech Inc (+51.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Grey Cloak Tech Inc (HYEX)?
The free-cash-flow yield on the price is 0.64 %: that much free cash flow Grey Cloak Tech Inc produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Grey Cloak Tech Inc (HYEX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Grey Cloak Tech Inc it is $0.3145 per share (as of Nov 12, 2026), against a price of $1.35. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Grey Cloak Tech Inc stock overvalued or undervalued in 2026?
As of Nov 12, 2026, HYEX trades above its calculated fair value: price $1.35, fair value $0.3145, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HYEX?
No. The price is what the market pays today ($1.35); the fair value is what the company's own numbers justify ($0.3145). For Grey Cloak Tech Inc the two are $1.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is Grey Cloak Tech Inc worth?
The market values Grey Cloak Tech Inc at about $22.8M (market capitalisation, as of Nov 12, 2026). Per share that is $1.35; our models calculate a fair value of $0.3145 per share.
What do the bullish and bearish scenarios say about HYEX?
Our models span a range for Grey Cloak Tech Inc: cautious scenario $0.1785, base $0.3145, optimistic $0.5695 per share (as of Nov 12, 2026, price $1.35). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Grey Cloak Tech Inc (HYEX)?
Balance-sheet figures for Grey Cloak Tech Inc (as of Nov 12, 2026): return on equity −7.7%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is HYEX from its 52-week high?
Grey Cloak Tech Inc trades at $1.35, about 50% below its 52-week high of $2.70 and 65% above the low of $0.8209 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3145 is for.
Which stocks are comparable to Grey Cloak Tech Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Grey Cloak Tech Inc stock attractive at the current price?
The data as of Nov 12, 2026: price $1.35, calculated fair value $0.3145 (−77%), Quality Score 35/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HYEX calculated?
We run Grey Cloak Tech Inc through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $0.3145 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Grey Cloak Tech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Grey Cloak Tech Inc (HYEX)?
The closing price on Nov 11, 2026 was $1.35. Our model-based fair value is $0.3145, about 77% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Grey Cloak Tech Inc right now?
The price sits above even our optimistic bull case ($0.5695). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($0.1785 to $0.5695). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Grey Cloak Tech Inc

How large is the market capitalisation of Grey Cloak Tech Inc (HYEX)?
The market capitalisation of Grey Cloak Tech Inc is $22.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Grey Cloak Tech Inc (HYEX)?
The price-to-sales ratio of Grey Cloak Tech Inc is 3.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Grey Cloak Tech Inc (HYEX)?
Earnings per share at Grey Cloak Tech Inc are $−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Grey Cloak Tech Inc (HYEX)?
The net margin of Grey Cloak Tech Inc is −14.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Grey Cloak Tech Inc (HYEX)?
The return on equity (ROE) of Grey Cloak Tech Inc is −7.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Grey Cloak Tech Inc (HYEX)?
On an EBIT basis the return on assets of Grey Cloak Tech Inc is −38.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Grey Cloak Tech Inc (HYEX)?
The operating margin of Grey Cloak Tech Inc is −2.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Grey Cloak Tech Inc (HYEX)?
Revenue at Grey Cloak Tech Inc is growing +113% versus a year earlier (3y avg +26.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Grey Cloak Tech Inc (HYEX)?
Earnings per share at Grey Cloak Tech Inc are growing −42.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Grey Cloak Tech Inc (HYEX) carry?
The net debt of Grey Cloak Tech Inc is $2.0M (fiscal year 2025, ≈ 13.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Grey Cloak Tech Inc in the live analysis

One click puts Grey Cloak Tech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.